Andrew Spencer
YOU?
Author Swipe
View article: An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01. Open
Background: Approximately 20% of NDMM patients (pts) demonstrate early therapeutic resistance, manifesting as primary refractoriness (1REF) to 1st-line therapy (1L) or early progression (EP) despite optimal induction therapy ± ASCT and len…
View article: Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.
Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. Open
Aim: To compare baseline characteristics, treatments and outcomes in newly diagnosed multiple myeloma (NDMM) patients based on the number of high-risk cytogenetic abnormalities (HRCA) present. Method: We analyzed Australian and New Zealand…
View article: Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone Open
Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab with bortezomib/lenalidomide/dexamethas…
View article: 3588 CLOX and neurotox: utility of clock drawing to monitor immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy
3588 CLOX and neurotox: utility of clock drawing to monitor immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy Open
View article: CS5 Cognitive recovery following immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy
CS5 Cognitive recovery following immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy Open
View article: Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis Open
Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We…
View article: HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma Open
The role of HAT-PCR (High A/T or High Annealing Temperature–PCR) in the quantification of minimal residual disease (MRD) was investigated in chronic lymphocytic leukemia (CLL) and myeloma. The IGH gene sequence was determined by next-gener…
View article: Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia Open
The survival of newly diagnosed patients with multiple myeloma has improved significantly over the past 20 years with significant therapeutic advances. Despite this, high‐dose chemotherapy followed by autologous stem cell transplantation r…
View article: <scp>CLOX</scp> and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy
<span>CLOX</span> and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy Open
Summary Immune effector cell‐associated neurotoxicity syndrome (ICANS)‐associated cognitive impairment is common in patients who receive chimeric antigen receptor T‐cell (CAR‐T) therapy. This study evaluated the utility of the clock drawin…
View article: ABS0150 ANTI-TL1A ANTIBODY REDUCES DISEASE SYMPTOMS AND PATHOLOGICAL CHANGES IN RAT COLLAGEN-INDUCED ARTHRITIS
ABS0150 ANTI-TL1A ANTIBODY REDUCES DISEASE SYMPTOMS AND PATHOLOGICAL CHANGES IN RAT COLLAGEN-INDUCED ARTHRITIS Open
View article: Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody Open
View article: Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era Open
Background Allogeneic haemopoietic stem cell transplantation (HSCT) is an effective therapy with curative potential for patients with high‐risk or relapsed/refractory chronic lymphocytic leukaemia (CLL). There are limited data on the use a…
View article: Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS Open
These data support use of D-VRd followed by D-R maintenance as standard of care for all transplant-eligible patients with NDMM, regardless of age up to 70 years.
View article: Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins Open
BH3 mimetic drugs that selectively target the pro-survival BCL2 proteins are highly promising for cancer treatment, most notably for treating blood cancers. Venetoclax, which inhibits BCL2, is now approved for treating chronic lymphocytic …
View article: Complete genome sequences of AZ <i>Arthrobacter</i> phages Wildwest and Sue2
Complete genome sequences of AZ <i>Arthrobacter</i> phages Wildwest and Sue2 Open
This announcement reports the complete genome sequences of two bacteriophages isolated from soil samples using the host Arthrobacter atrocyaneus Strain NRRL B-2883. These findings enhance our understanding of AZ1 cluster phages, particular…
View article: Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series
Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series Open
Background Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy …
View article: Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia Open
Background Regulatory bodies have recently approved chimeric antigen receptor (CAR)-T cell therapies for patients with multiple myeloma (MM), but the treatment process involves complex decision making. To support the introduction of these …
View article: Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma Open
View article: Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS Open
Early intervention in smoldering multiple myeloma (SMM) may delay progression to MM. Here, we present the final analysis of the phase 2 CENTAURUS study. In total, 123 patients with intermediate/high-risk SMM were randomized to IV daratumum…
View article: Multiple Myeloma Cells with Increased Proteasomal and ER Stress Are Hypersensitive to ATX-101, an Experimental Peptide Drug Targeting PCNA
Multiple Myeloma Cells with Increased Proteasomal and ER Stress Are Hypersensitive to ATX-101, an Experimental Peptide Drug Targeting PCNA Open
Objectives: To examine the regulatory role of PCNA in MM, we have targeted PCNA with the experimental drug ATX-101 in three commercial cell lines (JJN3, RPMI 1660, AMO) and seven in-house patient-derived cell lines with a more primary cell…
View article: Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma Open
Not available.
View article: A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma Open
The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adu…
View article: The impact of biomarkers of malignancy (<scp>IMWG SLiM</scp> criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (<scp>ANZ MRDR</scp>)
The impact of biomarkers of malignancy (<span>IMWG SLiM</span> criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (<span>ANZ MRDR</span>) Open
Summary A decade after International Myeloma Working Group (IMWG) biomarkers (SLiM criteria) were introduced, this real‐world study examined their impact on diagnosis, therapy and outcomes in myeloma. Using the ANZ MRDR, 3489 newly diagnos…
View article: Variation in immunoglobulin use and impact on survival in myeloma
Variation in immunoglobulin use and impact on survival in myeloma Open
Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few re…
View article: Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21
Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21 Open
Summary In Australia, bortezomib‐based induction (V‐IND) is used in >90% of newly diagnosed transplant‐eligible multiple myeloma (MM) patients. Four cycles of V‐IND with bortezomib–cyclophosphamide–dexamethasone or bortezomib–lenalidomide–…
View article: Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16 Open
In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. In a randomized trial, we tested whether similar improvements would be observed when daratumumab…
View article: The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR)
The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR) Open
Background Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM i…
View article: TIM-3 <sup>+</sup> CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
TIM-3 <sup>+</sup> CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies Open
Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed gra…
View article: Outcomes of Allogeneic Haematopoietic Transplant for Chronic Lymphocytic Leukaemia in the Modern Era
Outcomes of Allogeneic Haematopoietic Transplant for Chronic Lymphocytic Leukaemia in the Modern Era Open
There is limited data on the use and outcomes of allogeneic haematopoietic stem cell transplant (HSCT) in the modern era of chronic lymphocytic leukaemia (CLL) treatment. The aim of this study was to examine CLL transplant outcomes with a …
View article: Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines Open
Taken together, these studies suggest that CCR1 expression may be associated with decreased response to bortezomib in MM cell lines.